Welcome to the UPF Digital Repository

The type 1 diabetes gene TYK2 regulates β-cell development and its responses to interferon-α

Show simple item record

dc.contributor.author Chandra, Vikash
dc.contributor.author Ibrahim, Hazem
dc.contributor.author Halliez, Clémentine
dc.contributor.author Prasad, Rashmi B.
dc.contributor.author Vecchio, Federica
dc.contributor.author Dwivedi, Om Prakash
dc.contributor.author Kvist, Jouni
dc.contributor.author Balboa, Diego
dc.contributor.author Saarimäki-Vire, Jonna
dc.contributor.author Montaser, Hossam
dc.contributor.author Barsby, Tom
dc.contributor.author Lithovius, Väinö
dc.contributor.author Artner, Isabella
dc.contributor.author Gopalakrishnan, Swetha
dc.contributor.author Groop, Leif
dc.contributor.author Mallone, Roberto
dc.contributor.author Eizirik, Décio L.
dc.contributor.author Otonkoski, Timo
dc.date.accessioned 2023-01-24T07:20:00Z
dc.date.available 2023-01-24T07:20:00Z
dc.date.issued 2022
dc.identifier.citation Chandra V, Ibrahim H, Halliez C, Prasad RB, Vecchio F, Dwivedi OP, Kvist J, Balboa D, Saarimäki-Vire J, Montaser H, Barsby T, Lithovius V, Artner I, Gopalakrishnan S, Groop L, Mallone R, Eizirik DL, Otonkoski T. The type 1 diabetes gene TYK2 regulates β-cell development and its responses to interferon-α. Nat Commun. 2022 Oct 26;13(1):6363. DOI: 10.1038/s41467-022-34069-z
dc.identifier.issn 2041-1723
dc.identifier.uri http://hdl.handle.net/10230/55413
dc.description.abstract Type 1 diabetes (T1D) is an autoimmune disease that results in the destruction of insulin producing pancreatic β-cells. One of the genes associated with T1D is TYK2, which encodes a Janus kinase with critical roles in type-Ι interferon (IFN-Ι) mediated intracellular signalling. To study the role of TYK2 in β-cell development and response to IFNα, we generated TYK2 knockout human iPSCs and directed them into the pancreatic endocrine lineage. Here we show that loss of TYK2 compromises the emergence of endocrine precursors by regulating KRAS expression, while mature stem cell-islets (SC-islets) function is not affected. In the SC-islets, the loss or inhibition of TYK2 prevents IFNα-induced antigen processing and presentation, including MHC Class Ι and Class ΙΙ expression, enhancing their survival against CD8+ T-cell cytotoxicity. These results identify an unsuspected role for TYK2 in β-cell development and support TYK2 inhibition in adult β-cells as a potent therapeutic target to halt T1D progression.
dc.description.sponsorship We gratefully acknowledge Dr. Fatoumata Samassa for help with cytotoxicity assays. We thank Jarkko Ustinov for the insulin and c-peptide ELISA measurements. S. Eurola, H. Grym, and A. Laitinen are thanked for expert technical support. We thank FIMM Single Cell Analytics unit (supported by HiLIFE and Biocentre Finland) for single cell RNA sequencing services. We want to acknowledge the participants and investigators of the FinnGen study. T.O. acknowledges the funding provided by the Academy of Finland (MetaStem Center of Excellence grant 312437), the Novo Nordisk Foundation and the Sigrid Juselius Foundation. R.M. acknowledges the support of the Agence Nationale de la Recherche (ANR-19-CE15-0014-01) and the Fondation pour la Recherche Medicale (EQU20193007831). C.H. was funded by an Année Recherche fellowship of the Paris Saclay University. F.V. was funded by an international PhD fellowship of the IdEx Université de Paris. R.B.P. acknowledges the funding by Hjelt foundation, Crafoord foundation (2020089) and Swedish Research Council (2021-02623). D.L.E. acknowledges the support of grants from the Welbio-FNRS (Fonds National de la Recherche Scientifique; WELBIO-CR-2019C-04), Belgium; the Innovate2CureType1—Dutch Diabetes Research Foundation (DDRF), Holland; the Juvenile Diabetes Foundation (JDRF; 2-SRA-2019-834-S-B); the NIH (HIRN-CBDS) grant U01 DK127786, USA. D.L.E., T.O., and R.M. acknowledge support from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreements No 115797 (INNODIA) and 945268 (INNODIA HARVEST), supported by the European Union’s Horizon 2020 research and innovation programme. These Joint Undertakings receive support from the Union’s Horizon 2020 research and innovation programme and “EFPIA”, “JDRF” and “The Leona M. and Harry B. Helmsley Charitable Trust”.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Nature Research
dc.relation.ispartof Nat Commun. 2022 Oct 26;13(1):6363
dc.rights © The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
dc.rights.uri http://creativecommons.org/licenses/by/4.0/
dc.title The type 1 diabetes gene TYK2 regulates β-cell development and its responses to interferon-α
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1038/s41467-022-34069-z
dc.subject.keyword Cellular immunity
dc.subject.keyword Disease model
dc.subject.keyword Stem-cell differentiation
dc.subject.keyword Type 1 diabetes
dc.relation.projectID info:eu-repo/grantAgreement/EC/H2020/115797
dc.relation.projectID info:eu-repo/grantAgreement/EC/H2020/945268
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion


This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account


In collaboration with Compliant to Partaking